"Neuraltus won't release data from the Phase II trial of NP-001 until later this year, possibly next month. The drug last summer won Food and Drug Administration fast-track and orphan drug designations, which potentially could accelerate the clinical trial process by waiving FDA fees and providing tax breaks for the company's clinical trial costs."